

**Supplementary Table S2:**

Frequency of adverse effects after the first versus the second dose of BNT162b2 mRNA vaccine (given as percentage of all survey participants)

	After vaccine dose 1	After vaccine dose 2
<b>Any adverse effects</b>	79,5%	84,7%
<b>Inability to work</b>	7,9%	34,7%
<b>Local adverse effects</b>	73,0%	67,3%
Pain at injection site	70,7%	64,9%
Swelling	13,5%	13,8%
Redness	6,1%	6,3%
Itching at injection site	2,7%	2,2%
Rash at injection site	0,1%	0,2%
Urticaria at injection site	0,1%	0,0%
Other at injection site	2,4%	1,7%
<b>Systemic adverse effects</b>	42,8%	72,0%
Skin Rash	0,4%	0,9%
Generalized Itching	0,7%	0,6%
Urticaria	0,2%	0,2%
Local lymphadenopathy	3,4%	7,6%
Skin (Other)	0,4%	0,4%
Chills	4,1%	25,7%
Malaise	9,1%	29,2%
Nausea	3,4%	9,2%
Vomiting	0,3%	1,2%
Fatigue	25,1%	53,9%
Systemic (Other)	3,7%	5,5%
Headache	16,8%	38,0%
Limb Pain	6,4%	30,4%
Arthralgia	3,2%	13,2%
Myalgia	10,6%	19,1%
Pain (Other)	1,3%	2,7%
Feverish	2,1%	19,7%
Anaphylaxis	0,0%	0,0%
Anaphylactoid reactions	0,2%	0,3%
Facial paralysis	0,1%	0,1%
Nervous System (Other)	0,4%	0,9%
<b>Other adverse effects</b>	2,3%	5,1%